Molecular dynamics of the immune checkpoint programmed cell death protein I, PD-1: conformational changes of the BC-loop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab
Abstract Background The immune checkpoint receptor programmed cell death protein I (PD-1) has been identified as a key target in immunotherapy. PD-1 reduces the risk of autoimmunity by inducing apoptosis in antigen-specific T cells upon interaction with programmed cell death protein ligand I (PD-L1)...
Main Authors: | Bernhard Roither, Chris Oostenbrink, Wolfgang Schreiner |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-12-01
|
Series: | BMC Bioinformatics |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12859-020-03904-9 |
Similar Items
-
Targeting the PD-1/PD-L1 axis in the treatment of lung cancer
by: Matikas Alexios, et al.
Published: (2016-03-01) -
Aspectos farmacológicos do anticorpo monoclonal (Nivolumab) utilizando a Via PD-1 no tratamento antitumoral do Linfoma de Hodgkin
by: Fernanda Alves da SILVA, et al.
Published: (2019-04-01) -
PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse
by: Bingxin Zheng, et al.
Published: (2018-02-01) -
Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
by: Tomas Jelinek, et al.
Published: (2018-11-01) -
Long-Term Remission with Ipilimumab/Nivolumab in Two Patients with Different Soft Tissue Sarcoma Subtypes and No PD-L1 Expression
by: Maggie Zhou, et al.
Published: (2021-03-01)